On June 25, 2024, eFFECTOR Therapeutics, Inc., a biotechnology company, reported a significant financial event. The company received a notice from Oxford Finance LLC indicating that eFFECTOR Therapeutics has defaulted on certain obligations under a Loan and Security Agreement dated March 19, 2021. The notice specified that the defaults were due to a Material Adverse Change and Insolvency, as outlined in the agreement's sections 8.3 and 8.5. As a result, all obligations under the agreement have become immediately due and payable, and will accrue interest at the default rate. Oxford Finance LLC reserves all rights to enforce the agreement's terms. This development was disclosed in eFFECTOR Therapeutics' filing with the SEC and is a matter of concern for investors and stakeholders of the company.

On June 25, 2024, eFFECTOR Therapeutics, Inc., a biotechnology company, reported a significant financial event. The company received a notice from Oxford Finance LLC indicating that eFFECTOR Therapeutics has defaulted on certain obligations under a Loan and Security Agreement dated March 19, 2021. The notice specified that the defaults were due to a Material Adverse Change and Insolvency, as outlined in the agreement's sections 8.3 and 8.5. As a result, all obligations under the agreement have become immediately due and payable, and will accrue interest at the default rate. Oxford Finance LLC reserves all rights to enforce the agreement's terms. This development was disclosed in eFFECTOR Therapeutics' filing with the SEC and is a matter of concern for investors and stakeholders of the company.